Chongqing Zhifei Bio Products (300122) - Total Liabilities
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has total liabilities worth CN¥13.38 Billion CNY (≈ $1.96 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300122 net asset momentum to track the company's year-over-year net asset growth rate.
Chongqing Zhifei Bio Products - Total Liabilities Trend (2007–2025)
This chart illustrates how Chongqing Zhifei Bio Products's total liabilities have evolved over time, based on quarterly financial data. See Chongqing Zhifei Bio Products (300122) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Chongqing Zhifei Bio Products Competitors by Total Liabilities
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RadNet Inc
NASDAQ:RDNT
|
USA | $2.53 Billion |
|
Bendigo and Adelaide Bank Ltd
AU:BEN
|
Australia | AU$96.55 Billion |
|
Beibuwan Port Co Ltd
SHE:000582
|
China | CN¥17.32 Billion |
|
Wacker Chemie AG
XETRA:WCH
|
Germany | €4.68 Billion |
|
BillionToOne, Inc. Class A Common Stock
NASDAQ:BLLN
|
USA | $195.11 Million |
|
Iridium Communications Inc
NASDAQ:IRDM
|
USA | $2.06 Billion |
|
Primoris Services Corporation
NYSE:PRIM
|
USA | $3.02 Billion |
|
Thai Oil Public Company Limited
BK:TOP
|
Thailand | ฿234.25 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Chongqing Zhifei Bio Products's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Chongqing Zhifei Bio Products.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chongqing Zhifei Bio Products's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chongqing Zhifei Bio Products (2007–2025)
The table below shows the annual total liabilities of Chongqing Zhifei Bio Products from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥15.61 Billion ≈ $2.28 Billion |
-18.16% |
| 2024-12-31 | CN¥19.08 Billion ≈ $2.79 Billion |
+1.88% |
| 2023-12-31 | CN¥18.73 Billion ≈ $2.74 Billion |
+36.02% |
| 2022-12-31 | CN¥13.77 Billion ≈ $2.01 Billion |
+11.12% |
| 2021-12-31 | CN¥12.39 Billion ≈ $1.81 Billion |
+77.73% |
| 2020-12-31 | CN¥6.97 Billion ≈ $1.02 Billion |
+34.19% |
| 2019-12-31 | CN¥5.20 Billion ≈ $760.20 Million |
+97.59% |
| 2018-12-31 | CN¥2.63 Billion ≈ $384.75 Million |
+125.04% |
| 2017-12-31 | CN¥1.17 Billion ≈ $170.97 Million |
+520.77% |
| 2016-12-31 | CN¥188.21 Million ≈ $27.54 Million |
-11.39% |
| 2015-12-31 | CN¥212.40 Million ≈ $31.08 Million |
-17.26% |
| 2014-12-31 | CN¥256.72 Million ≈ $37.57 Million |
+29.26% |
| 2013-12-31 | CN¥198.61 Million ≈ $29.06 Million |
+52.15% |
| 2012-12-31 | CN¥130.53 Million ≈ $19.10 Million |
-10.73% |
| 2011-12-31 | CN¥146.22 Million ≈ $21.40 Million |
+116.35% |
| 2010-12-31 | CN¥67.59 Million ≈ $9.89 Million |
+1.89% |
| 2009-12-31 | CN¥66.33 Million ≈ $9.71 Million |
-46.09% |
| 2008-12-31 | CN¥123.05 Million ≈ $18.01 Million |
-14.71% |
| 2007-12-31 | CN¥144.27 Million ≈ $21.11 Million |
-- |
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more